Nicholas Murray

AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME

Bethan Lang, Dennis Wray, John Newsom–Davis et al. · The Lancet · 1981 · 366 citations

Autoimmune Disease, Autoimmunity, Autoantibodies +5

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

K. N., Martin Gleave, Richard Klasa et al. · PubMed · 2001 · 191 citations

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

David Cameron, James P. Morden, Peter Canney et al. · The Lancet Oncology · 2017 · 73 citations · Full text

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Quincy S. Chu, Mary Cianfrocca, Lori J. Goldstein et al. · Clinical Cancer Research · 2008 · 71 citations

Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor.

John Newsom–Davis, Nicholas Murray, D. Wray et al. · PubMed · 1982 · 51 citations

Immunology, Dermatology, Lems Plasma +18